Achromatopsia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Achromatopsia Analysis report covers 3 drugs currently in different phases of development. Achromatopsia is an inherited autosomal recessive disorder characterised by partial or total absence of coloured vision and is also characterised with decreased vision, light sensitivity, and nystagmus (involuntary back-and-forth eye movements). A human eye have approximately 6 million cone photoreceptors mainly located at the center of the retina and around 100 million rod photoreceptors which are located at the periphery of the retina. People with achromatopsia lacks cone photoreceptor cells in the eye and have to rely on the rod photoreceptors which do not provide detailed vision and good colour vision.
The report provides Achromatopsia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report Applied Genetic Technologies Corp, MeiraGTx Limited, Athena Vision, Regenxbio Inc. and Biogen Inc.
By Molecule Type
By Route of Administration